Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

Ruth Webster; Adrianna Murphy; Helen Bygrave; Éimhín Ansbro; Diederick E Grobbee; Pablo Perel

doi:10.5334/gh.860

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

Ruth Webster^*
, Adrianna Murphy
, Helen Bygrave
, Éimhín Ansbro
, Diederick E Grobbee
, Pablo Perel

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Downloads (Pure)

Abstract

Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

Original language	English
Article number	57
Journal	Global Heart
Volume	15
Issue number	1
DOIs	https://doi.org/10.5334/gh.860
Publication status	Published - 19 Aug 2020

Keywords

Cardiovascular Prevention
Combination therapy
Hypertension
Polypills
Public Health

Access to Document

10.5334/gh.860

860-1-2579-1-10-20200819Final published version, 940 KBLicence: Taverne

Cite this

@article{8a078bcc516c4487bf152f12e63cfd24,

title = "Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases",

abstract = "Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.",

keywords = "Cardiovascular Prevention, Combination therapy, Hypertension, Polypills, Public Health",

author = "Ruth Webster and Adrianna Murphy and Helen Bygrave and {\'E}imh{\'i}n Ansbro and Grobbee, \{Diederick E\} and Pablo Perel",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = aug,

day = "19",

doi = "10.5334/gh.860",

language = "English",

volume = "15",

journal = "Global Heart",

issn = "2211-8160",

publisher = "Ubiquity Press",

number = "1",

}

TY - JOUR

T1 - Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

AU - Webster, Ruth

AU - Murphy, Adrianna

AU - Bygrave, Helen

AU - Ansbro, Éimhín

AU - Grobbee, Diederick E

AU - Perel, Pablo

PY - 2020/8/19

Y1 - 2020/8/19

N2 - Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

AB - Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

KW - Cardiovascular Prevention

KW - Combination therapy

KW - Hypertension

KW - Polypills

KW - Public Health

UR - https://www.scopus.com/pages/publications/85090872301

U2 - 10.5334/gh.860

DO - 10.5334/gh.860

M3 - Editorial

C2 - 32923350

SN - 2211-8160

VL - 15

JO - Global Heart

JF - Global Heart

IS - 1

M1 - 57

ER -

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this